← 返回

浸润肿瘤的 CD8+ T 细胞受肺淋巴结免疫状态调控,并与接受化疗免疫治疗的非小细胞肺癌(NSCLC)患者预后相关

英文原题:CD8+ T cells infiltrating into tumors were controlled by immune status of pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC) patients' prognosis treated with chemoimmunotherapy.

查看英文原题

CD8+ T cells infiltrating into tumors were controlled by immune status of pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC) patients' prognosis treated with chemoimmunotherapy.

PubMed 2024/10/15(内容时间) Lung Cancer Q1 · IF 5.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

肺 LN 和 TME 中的免疫细胞共同影响 NSCLC 患者 TME 的重塑,从而影响治疗反应和预后。

研究思路结论见上方概要

新辅助化疗免疫治疗有可能减轻肿瘤负荷、提高病理完全缓解(pCR)率,并显著延长患者的无病生存期(DFS)。然而,该治疗在NSCLC患者中的有效性存在差异。促进肿瘤消退的免疫机制仍需进一步探索和阐明。

采用多重免疫荧光分析患者新辅助化免疫治疗前后局部肿瘤微环境(TME)的免疫状态、治疗后配对的肺淋巴结(第11组淋巴结),包括浸润免疫细胞密度及其相关性。

共纳入56例接受新辅助化疗免疫治疗的NSCLC患者,随后接受手术切除和病理评估。其中,19例患者达到pCR,6例患者表现出主要病理缓解(MPR),31例患者未达到MPR。在新辅助治疗前,患者TME中CD8+ T细胞、Treg和树突状细胞(DC)的密度无显著差异(n = 26,P = 0.091,P = 0.753,P = 0.905),但治疗后,这些免疫细胞的动态变化在不同缓解组之间存在显著差异。CD8+ T细胞密度在pCR组中升高(P = 0.006),但在非pCR组中未升高(P = 0.389);Treg密度在非pCR组中升高(P = 0.0004),但DC在非pCR组中显著降低(P = 0.005)。手术后,TME也存在显著差异:达到pCR的患者通常表现出高密度的CD8+ T细胞、DC和低密度的Treg(P = 0.0001,P < 0.0001和P = 0.0004)。第11组淋巴结的免疫状态也表现出显著差异。pCR患者的DC密度更高,而pCR组的Treg显著低于非pCR组(P = 0.0008和P = 0.003)。此外,TME中DC的密度与第11组淋巴结中DC呈中度正相关(P = 0.0002),而TME中Treg的密度与第11组淋巴结中DC密度呈中度负相关(P = 0.03)。切除组织中CD8+ T细胞密度高且淋巴结中DC密度高的患者,DFS更长(P = 0.048和P = 0.024)。

展开英文摘要原文

Neoadjuvant chemoimmunotherapy has the potential to reduce tumor burden, improve the pathological complete response (pCR) rate, and significantly prolong patients' disease-free survival (DFS). However, the treatment's effectiveness varies among NSCLC patients. The immunological mechanisms contributing to tumor regression still require further exploration and elucidation.

The immune status of patients' local tumor microenvironment (TME) before and after neoadjuvant chemoimmunotherapy, their paired pulmonary lymph nodes (11th LNs) after therapy, including infiltrating immune cell densities and their correlations, were analyzed using multiplex immunofluorescence.

Fifty-six NSCLC patients undergoing neoadjuvant chemoimmunotherapy were enrolled and subsequently underwent surgical resection and pathological evaluation. Among these, 19 patients achieved a pCR, 6 patients exhibited a major pathological response (MPR), and 31 patients did not achieve MPR. There were no significant difference in the densities of CD8+ T cell, Treg and Dendritic cell (DC) in patients' TME before neoadjuvant therapy (n = 26, P = 0.091, P = 0.753, P = 0.905, respectively), but after treament, these immune cells' dynamics were significantly different between different response group. CD8+ T cell densities were increased in pCR gourp (P = 0.006), but not in non-pCR group (P = 0.389); the densities of Treg were increased in non-pCR gourp (P = 0.0004), but DC were significantly decreased in non-pCR gourp (P = 0.005). After surgery, the TME were also significantly different: patients achieving pCR typically demonstrated high densities of CD8+ T cell, DC and low densities of Tregs (P = 0.0001, P < 0.0001 and P = 0.0004). The immune status of 11th LNs also exhibited significant differences. DC densities were much higher in pCR patients, whereas Treg in the pCR group were significantly lower than those in the non-pCR group (P = 0.0008 and P = 0.003). Furthermore, the densities of DC in the TME showed a moderate positive correlation with DC in 11th LNs (P = 0.0002), while the densities of Tregs in the TME exhibited a moderate negative correlation with DC densities in 11th LNs (P = 0.03). Patients who had high densities of CD8+ T cell in the resection tissues and DC in the LNs, experienced longer DFS (P = 0.048 and P = 0.024).

Immune cells in both pulmonary LNs and the TME collectively influence the remodeling of the NSCLC patient's TME, thus impacting treatment response and prognosis.

论文信息

作者
Bai Z、Cheng X、Ma T、Li G、Wang X、Wang Z、Yi L、Liu Z
第一作者单位
No. 2 Department of Thoracic Surgery, Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing Chest Hospital, Capital Medical University, Beijing, China.China
通讯作者单位
No. 2 Department of Thoracic Surgery, Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing Chest Hospital, Capital Medical University, Beijing, China. Electronic address: liuzhidong@bjxkyy.cn.China
文献类型
非美国政府资助研究
期刊
Lung cancer (Amsterdam, Netherlands)2024 Nov
原文标识
PubMed 39454350 · DOI 10.1016/j.lungcan.2024.107991